Dr. Raphael Mechoulam (1930–2023) — The Father of Cannabinoid Research

Raphael Mechoulam's biography begins in the catastrophe of 20th-century European Jewry and ends in the founding of an entire field of pharmacology. His father survived a Nazi labor camp. His family reached Israel in 1949, the year after independence. Mechoulam earned his PhD at the Weizmann Institute of Science in 1958 and completed a postdoctoral fellowship at the Rockefeller Institute in New York. He then returned to Israel and spent the next sixty years at the Hebrew University of Jerusalem, where he would identify the most important molecules in cannabis science.

The research question

Mechoulam's starting point was a simple observation: by the early 1960s, morphine had been isolated from opium and cocaine had been isolated from coca leaves, but no one had identified the active compound in cannabis. The most widely used illicit drug in the world was pharmacologically uncharacterized. Mechoulam set out to fill the gap.

The hashish on the bus

To conduct his research, Mechoulam needed cannabis. He requested five kilograms of confiscated hashish from the Israeli police. They gave it to him. He rode it home on a public bus — a detail he recounted in interviews for decades, to the amusement of interviewers and the retrospective horror of university compliance officers. The hashish was his raw material for the isolation work that followed.

Isolating CBD and THC

The 1964 JACS paper is the founding document of modern cannabinoid chemistry. It identified the molecule responsible for cannabis intoxication, determined its structure, and synthesized it. For the first time, scientists knew exactly what cannabis did and which molecule did it. Every subsequent advance in cannabis pharmacology — medical applications, drug testing, receptor identification, the endocannabinoid system — flows from Mechoulam's 1964 isolation.

Mechoulam and his colleagues also identified CBG (cannabigerol) and THCA (tetrahydrocannabinolic acid) shortly afterward, mapping out the major cannabinoid family that would define the field for decades.

Anandamide and the endocannabinoid system

The discovery of anandamide was arguably more significant than the isolation of THC itself. It revealed that the human body produces its own cannabis-like molecules — endocannabinoids — that bind to specific receptors throughout the brain and body. The endocannabinoid system, as it came to be known, is involved in pain modulation, appetite, mood, memory, immune function, and a range of other physiological processes.

The naming choice — ananda, Sanskrit for "bliss" — reflects Mechoulam's literary sensibility. A Bulgarian-Israeli chemist named an endogenous neurotransmitter after a Sanskrit concept. The word has become standard pharmacological terminology.

Sixty years at Hebrew University

Mechoulam spent his entire post-doctoral career at the Hebrew University of Jerusalem — sixty years of continuous research at a single institution. He published more than 440 scientific papers. He trained generations of cannabinoid researchers. He established Israel as the global center of cannabis science, a position it retains.

He was awarded the Israel Prize, the Rothschild Prize, and numerous international honors. He was frequently cited as a candidate for the Nobel Prize in Chemistry or Physiology. The Nobel never came — a fact that many in the field regard as an injustice shaped by the stigma surrounding cannabis research rather than by the quality of the science.

Death

Assessment

Mechoulam's contribution to science is not a matter of debate. He identified the molecules that explain what cannabis does, discovered the biological system that explains why it works, and published the foundational papers that every subsequent cannabis researcher builds on. The field of cannabinoid pharmacology exists because of his work.

The informal consensus among cannabis scientists — "He should have won a Nobel Prize" — reflects a broader truth about the relationship between scientific merit and cultural stigma. Mechoulam spent sixty years studying a plant that most of the world's governments classified as having no medical value. His work proved otherwise. The governments were wrong. The science was right.